Product image of Juzimette (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Juzimette

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Juzimette (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Juzimette, is a biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control.

GNH India supplies Juzimette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Polska Sp. Z. O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Juzimette is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • Inadequate control on metformin alone: provides additional glucose‑lowering effect when added to existing therapy.
  • Combination therapy with other antidiabetics: enhances overall glycaemic management while allowing dose reduction of individual agents.

How It Works

  • Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits dipeptidyl peptidase‑4, prolonging incretin activity and promoting glucose‑dependent insulin secretion. The complementary actions result in decreased hepatic glucose output and increased insulin release after meals, improving overall glycaemic control in type 2 diabetes.

Side Effects

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
  • Headache: mild to moderate intensity.
  • Mild hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Metallic taste: transient alteration in taste perception.
  • Weight neutrality: no significant change in body weight.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic complication.
  • Acute pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe hypoglycaemia: prolonged low blood glucose requiring assistance.
  • Allergic reactions: rash, pruritus, or angio‑edema.
  • Hepatic dysfunction: elevated transaminases or liver injury.
  • Renal impairment: worsening kidney function, especially with metformin accumulation.

Precautions & Warnings

Before prescribing Juzimette, clinicians should consider several safety aspects.

  • Renal function assessment: evaluate eGFR and avoid use in severe renal impairment.
  • Hepatic disease: contraindicated in patients with significant liver dysfunction.
  • Risk of lactic acidosis: discontinue if symptoms of acidosis develop.
  • Pregnancy and lactation: use only if potential benefit justifies risk.
  • Drug interaction review: assess concomitant medications that may affect clearance.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Juzimette may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase sitagliptin plasma concentrations.
  • Iodinated contrast agents with metformin: heightened risk of renal dysfunction and lactic acidosis.
  • Concurrent insulin secretagogues: increased risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Diuretics: can affect renal clearance of metformin, necessitating dose adjustment.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.
  • Beta‑blockers: may mask hypoglycaemia symptoms, requiring patient education.

Frequently Asked Questions

Juzimette is prescribed for the management of type 2 diabetes mellitus. It combines metformin, which improves insulin sensitivity, with sitagliptin, which enhances insulin secretion in response to meals, helping to achieve better overall blood‑glucose control.

Metformin lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, reducing the amount of glucose produced by the liver, and by increasing peripheral tissue sensitivity to insulin, which facilitates glucose uptake into muscles and fat cells.

The dosage of Juzimette is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the dose regimen provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. The drug should only be used if the potential benefits outweigh the risks, and this decision must be made by the treating physician after a thorough assessment.

Enquiries can be submitted via the product page on gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Juzimette offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and insulin‑secretagogue effects in a single tablet. This can simplify regimens compared with taking separate agents and may improve adherence versus multiple‑pill therapies.

Store Juzimette at ambient temperature, below 25 °C, in the original blister pack or container. Protect the tablets from moisture, direct sunlight and excessive heat to maintain product stability.

Juzimette is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and acute pancreatitis related to sitagliptin. Patients should be educated to seek immediate medical attention if they experience severe abdominal pain, unexplained fatigue, or rapid breathing.

Juzimette is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), significant hepatic disease, a history of lactic acidosis, or known hypersensitivity to either metformin or sitagliptin. It should also be avoided in individuals with type 1 diabetes.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT